Bayer AG / KaNDy Therapeutics Ltd.

Vasomotor Symptoms (VMS) of Menopause

$7.3B Global menopausal hot flashes market 2025E (Mordor Intelligence)

Disease Overview

Vasomotor symptoms — hot flashes and night sweats — affect up to 75-80% of women during the menopause transition, with about a third experiencing moderate-to-severe symptoms that disrupt sleep and quality of life. Hormone replacement therapy is effective but carries oncologic and cardiovascular risk concerns following the Women's Health Initiative findings, leaving a large addressable population for non-hormonal alternatives.

Competitive Landscape

The non-hormonal VMS class crystallized around neurokinin-3 (NK3) receptor antagonism of the hypothalamic KNDy neurons that regulate the thermoregulatory center. Astellas' fezolinetant (Veozah) was the first NK3 antagonist to reach the FDA finish line, approved in May 2023 for moderate-to-severe VMS — at the time of the 2020 Bayer-KaNDy deal, fezolinetant was in Phase 3, making it the established competitor. Off-label paroxetine (Brisdelle, the only FDA-approved non-hormonal VMS therapy at deal time), gabapentin, clonidine, and SSRIs/SNRIs constituted the standard-of-care non-hormonal options, all with limited efficacy. Estrogen-based HRT (Premarin, Estrace, transdermal patches) remained dominant in commercial volume but carried Black Box warnings post-WHI. NT-814 / elinzanetant differentiated as a dual NK1/NK3 antagonist — adding NK1 blockade was hypothesized to address sleep and mood symptoms beyond pure thermoregulation, a mechanistic edge over fezolinetant's single-NK3 approach. Bayer's $425M upfront / $450M milestones plus undisclosed sales milestones reflected confidence in beating Astellas on label breadth; FierceBiotech framed the deal as Bayer 'challenging Astellas for menopause market'. Elinzanetant was ultimately FDA-approved as Lynkuet in October 2025.